Imexpharm Corporation (HOSE:IMP)

Vietnam flag Vietnam · Delayed Price · Currency is VND
50,100
+1,550 (3.19%)
At close: Oct 31, 2025
3.19%
Market Cap7.72T
Revenue (ttm)2.45T
Net Income (ttm)333.14B
Shares Out154.01M
EPS (ttm)2,163.10
PE Ratio23.16
Forward PE23.17
Dividend500.00 (1.03%)
Ex-Dividend DateJun 9, 2025
Volume54,549
Average Volume42,682
Open48,500
Previous Close48,550
Day's Range48,000 - 50,100
52-Week Range36,100 - 56,500
Beta0.72
RSI45.96
Earnings DateJan 16, 2026

About Imexpharm

Imexpharm Corporation manufactures, processes, trades, imports, and exports pharmaceutical products in Vietnam and internationally. The company’s products include oral and injectable antibiotic, digestion, central nervous system, cardiovascular, diabetes, ophthalmology, musculoskeletal system, respiratory system, analgesic-anti-inflammatory- antipyretics, anti-histamines, anti-allergy, anti-parasitic, and external drugs, as well as vitamins and minerals, and supplement. It is also involved in the import and export of medical equipment and suppl... [Read more]

Industry Pharmaceutical Preparations
Founded 1977
Employees 1,452
Stock Exchange Ho Chi Minh Stock Exchange
Ticker Symbol IMP
Full Company Profile

Financial Performance

In 2024, Imexpharm's revenue was 2.21 trillion, an increase of 10.59% compared to the previous year's 1.99 trillion. Earnings were 297.54 billion, an increase of 7.11%.

Financial Statements

News

There is no news available yet.